Emergent BioSolutions Inc.
corporate_fare Company Profile
Emergent BioSolutions Inc. (NYSE:EBS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for EBS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for EBS spans 8-K, 10-Q, DEFA14A.
Recent high-impact activity:
- CFO to Retire Dec. 31; Treasurer Vargo Named Interim Finance Chief
- Emergent CFO Lindahl to Retire Dec 31; Treasurer Frank Vargo Named Interim CFO
- Emergent BioSolutions Sets Q3 Revenue Guidance at $110M-$130M and Outlines Debt Reduction
- Emergent BioSolutions Wins $24M BARDA Contract for Anthrax Vaccine CYFENDUS
- Emergent BioSolutions Posts $180M Q2 Loss on $191M NARCAN Impairment, Announces Restructuring to Save $40M
Financial Snapshot
Short Interest & Short Volume
9.02 days to coverFINRA reported short interest of 9,684,744 shares in EBS as of the October 15, 2026 settlement, a 4.2% increase from the prior period — about 9.0 days to cover at its recent average daily volume. On October 30, 2026, 53.3% of EBS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.